BDX

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 193.71 USD with a low forecast of 183.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Becton Dickinson and Co revenue for the last quarter amounts to 5.89B USD, increased 8.35 % YoY.

Becton Dickinson and Co. EPS for the last quarter amounts to 1.71 USD, increased 24.82 % YoY.

Becton Dickinson and Co (BDX) has 72000 emplpoyees as of December 17 2025.

Today BDX has the market capitalization of 56.05B USD.